natgillin/translations-raw huggingface dataset:
Bosutinib has no or negligible influence on the ability to drive and use machines.
Bosutinib nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
The relationship between the observed effects and medicinal product treatment were inconclusive.
O povezavi med opaženimi učinki in uporabo zdravila ni dokončnih zaključkov.
In these situations an individual benefit-risk assessment is mandatory and patients should be monitored for occurrence of QTc prolongation.
V tem primeru je obvezna individualna ocena razmerja med koristjo in tveganjem, bolnike pa je treba spremljati glede pojava podaljšanja QTc.
Includes patients (N) who attained or maintained MCyR.
Vključuje bolnike (n), ki so dosegli ali ohranili MCyR.
Including patients (N) who received at least 1 dose of bosutinib.
Vključno z bolniki (n), ki so prejeli vsaj 1 odmerek bosutiniba.
If you are taking any of them, tell your doctor.
Če jemljete katerokoli izmed njih, obvestite zdravnika.
- if you have heart problems.
- Če imate težave s srcem.
- if you have been told that you have problems with your kidneys.
- Če so vam povedali, da imate težave z ledvicami.
If you are not able to take the medicine as your doctor prescribed or you feel you do not need it anymore, contact your doctor right away.
Če zdravila niste sposobni jemati tako, kot je predpisal zdravnik, ali če imate občutek, da ga ne potrebujete več, nemudoma obvestite zdravnika.
Frequency categories are defined as: very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare ( 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Pogostnost neželenih učinkov je opredeljena na naslednji način: zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1.000 do < 1/100), redki ( 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Bosulif is indicated for the treatment of adult patients with:
Zdravilo Bosulif je indicirano za zdravljenje odraslih bolnikov:
You must immediately contact your doctor if you experience any of those serious side effects (see also section 2 “What you need to know before you take Bosulif”):
Nemudoma se posvetujte z zdravnikom, če opazite kateregakoli od naslednjih resnih neželenih učinkov (glejte tudi poglavje 2 “Kaj morate vedeti, preden boste vzeli zdravilo Bosulif”):
An effect on male fertility cannot be excluded (see section 4.6).
Učinka na plodnost pri moških ni mogoče izključiti (glejte poglavje 4.6).
The medicines listed here may not be the only ones that could interact with Bosulif.
Našteta zdravila morda niso edina, ki bi lahko medsebojno delovala z zdravilom Bosulif.
Patients who take an overdose of bosutinib should be observed and given appropriate supportive treatment.
Bolnike, ki so vzeli prevelik odmerek bosutiniba, je treba spremljati in uvesti ustrezno podporno zdravljenje.
A proarrhythmic potential of bosutinib cannot be ruled out.
Proaritmičnega potenciala bosutiniba ni mogoče izključiti.
This is called tumour lysis syndrome and can cause kidney failure and heart problems within 48 hours of the first dose of Bosulif.
To se imenuje sindrom lize tumorja in lahko povzroči odpoved ledvic in težave s srcem v 48 urah po prejemu prvega odmerka zdravila Bosulif.
Bosulif should be taken orally once daily with food (see section 5.2).
Zdravilo Bosulif je treba jemati peroralno, enkrat na dan, s hrano (glejte poglavje 5.2).
If recovery takes longer than 4 weeks, discontinuation of bosutinib should be considered.
Če okrevanje traja dlje kot 4 tedne, je treba razmisliti o prekinitvi zdravljenja z bosutinibom.
The p-values for endpoints other than MMR at 12 months and CCyR by 12 months have not been adjusted for multiple comparisons.
Vrednosti p za druge opazovane dogodke, razen MMR po 12 mesecih in CCyR po 12 mesecih, niso prilagodili za večkratne primerjave.
Severe skin reactions
Hude kožne reakcije
Tell your doctor if you are urinating more frequently and producing larger amounts of urine with a pale colour or if you are urinating less frequently and producing smaller amounts of urine with a dark colour.
Obvestite zdravnika, če urinirate bolj pogosto in proizvajate večje količine urina blede barve ali če urinirate manj pogosto in proizvajate manjše količine urina temne barve.
One patient on bosutinib and 7 patients on imatinib died while on study.
En bolnik na bosutinibu in 7 bolnikov na imatinibu je med študijo umrlo.
One patient with the E255V mutation previously treated with nilotinib achieved CHR as best response.
En bolnik z mutacijo E255V, ki je bil predhodno zdravljen z nilotinibom, je kot najboljši odziv dosegel CHR.
Do not stop taking Bosulif unless your doctor tells you to do so.
Ne prenehajte z jemanjem zdravila Bosulif, razen če vam to naroči zdravnik.
Absorption was relatively slow, with a median time-to-peak concentration (tmax) reached after 6 hours.
Absorpcija je bila relativno počasna, z medianim časom do največje koncentracije (tmax) 6 ur.
Ph-positive CML is a cancer of the blood which makes the body produce too many of a specific type of white blood cell called granulocytes.
Ph-pozitivna kronična mieloična levkemija je krvni rak, zaradi katerega telo izdeluje preveliko količino določenih belih krvnih celic, imenovanih granulociti.
Bosutinib did not have effects on respiratory functions.
Bosutinib ni vplival na dihalne funkcije.
The safety and efficacy of bosutinib in children and adolescents less than 18 years of age have not been established.
Varnost in učinkovitost bosutiniba pri otrocih in mladostnikih, mlajših od 18 let, nista bili dokazani.
If you have any questions about how Bosulif works or why this medicine has been prescribed for you, ask your doctor.
Če imate kakršnakoli vprašanja o tem, kako zdravilo Bosulif deluje, ali zakaj vam je bilo to zdravilo predpisano, se posvetujte z zdravnikom.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription, vitamins, and herbal medicines.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo, vključno z zdravili brez recepta, vitamini in zdravili rastlinskega izvora.
Doses greater than 600 mg/day have not been studied and, therefore, should not be given.
Odmerkov, večjih od 600 mg na dan, niso preučevali in se jih zato ne sme uporabljati.
Swallow the tablet(s) whole with water.
Tableto (tablete) pogoltnite celo (cele) z vodo.
Your doctor may change the dose of these medicines, change the dose of Bosulif, or switch you to a different medicine.
Zdravnik bo morda spremenil odmerek teh zdravil, odmerek zdravila Bosulif ali pa vam bo predpisal drugo zdravilo.
Clinical signs of toxicity included foecal changes and were associated with decreased food consumption and body weight loss which occasionally led to death or elective euthanasia.
Klinični znaki toksičnosti so vključevali spremembe blata in so bili povezani z zmanjšanim vnosom hrane in zmanjšanjem telesne mase, kar je občasno privedlo do smrti ali elektivne evtanazije.
You should inform your doctor if you are taking medicines containing active substances such as those listed below:
Obvestite zdravnika, če jemljete zdravila, ki vsebujejo učinkovine, navedene v nadaljevanju:
Snapshot date: 02Oct2015
Datum zajema podatkov: 2. oktober 2015
What Bosulif is and what it is used for
Kaj je zdravilo Bosulif in za kaj ga uporabljamo
Effects of bosutinib on other medicinal products
Vpliv bosutiniba na druga zdravila
No specific dose recommendation is necessary in the elderly.
Pri starejših niso potrebna posebna priporočila glede odmerjanja.
Your doctor may adjust the dose using the 100 mg tablets depending upon your medical conditions, upon your response to treatment and/or on any side effect you may experience.
Zdravnik bo morda prilagodil odmerek z uporabo 100 mg tablet, odvisno od vašega stanja, odziva na zdravljenje in/ali pojava neželenih učinkov.
Hepatic impairment (see sections 5.1 and 5.2).
Okvara jeter (glejte poglavji 5.1 in 5.2).
Bosutinib can induce severe skin reactions such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Bosutinib lahko povzroči hude kožne reakcije, kot sta Stevens-Johnsonov sindrom in toksična epidermalna nekroliza.
- if you have any of these symptoms: serious skin rashes.
- Če se vam pojavi kateri od simptomov resnih kožnih izpuščajev.
Table 4 - Comparison of MMR at Months 3, 6, and 9 by treatment in the mITT population
Preglednica 4 - Primerjava MMR po 3, 6 in 9 mesecih glede na vrsto zdravljenja v populaciji mITT
This allowed measurable concentrations of radioactivity to appear in the plasma of nursing pups.
To je omogočilo, da so se v plazmi dojenih mladičev pojavile merljive koncentracije radioaktivnosti.
Dose adjustments for renal impairment were based on the results of this study, and the known linear pharmacokinetics of bosutinib in the dose range of 200 to 600 mg.
Prilagajanje odmerka pri okvari ledvic temelji na rezultatih te študije in znane linearne farmakokinetike bosutiniba v razponu odmerkov od 200 do 600 mg.
Elevation in serum lipase has been observed.
Opazili so povečane vrednosti serumske lipaze.
Genotoxicity studies in bacterial in vitro systems and in mammalian in vitro and in vivo systems with and without metabolic activation did not reveal any evidence for a mutagenic potential of bosutinib.
V študijah genotoksičnosti na bakterijskih sistemih in vitro ter na sistemih sesalcev in vitro in in vivo, z metabolično aktivacijo ali brez nje, niso zasledili nobenega dokaza za mutageni potencial bosutiniba.
The European Medicines Agency has deferred the obligation to submit the results of studies with Bosulif in one or more subsets of the paediatric population in CML (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Bosulif za eno ali več podskupin pediatrične populacije pri zdravljenju KML (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
The study results indicate that bosutinib does not exhibit clinically relevant P-gp inhibitory effects.
Rezultati študije kažejo, da bosutinib ne kaže klinično pomembnih zaviralnih učinkov P-gp.
Recurrence (reactivation) of hepatitis B infection when you have had hepatitis B in the past (a liver infection).
Reaktivacija hepatitisa B: Ponovitev (reaktivacija) okužbe s hepatitisom B, če ste imeli hepatitis B v preteklosti (okužba jeter).
There is a risk that treatment with Bosulif will lead to decreased fertility and you may wish to seek advice about sperm storage before the treatment starts.
Obstaja tveganje, da bo zdravljenje z zdravilom Bosulif povzročilo zmanjšanje plodnosti, zato se boste pred začetkom zdravljenja morda želeli posvetovati glede shranjevanja sperme.
In clinical trials for both indications, treatment with bosutinib continued until disease progression or intolerance to therapy.
V kliničnih preskušanjih za obe indikaciji se je zdravljenje z bosutinibom nadaljevalo do napredovanja bolezni ali neprenašanja zdravljenja.
Treatment of nausea or vomiting with such medicines together with Bosulif may result in a greater risk of dangerous heart arrhythmias.
Zdravljenje siljenja na bruhanje ali bruhanja s temi zdravili skupaj z zdravilom Bosulif lahko povzroči večje tveganje za pojav nevarnih srčnih aritmij.
- if you have or have had pancreas problems.
- Če imate ali ste imeli težave s trebušno slinavko.
If clinically appropriate, re-escalation to the dose prior to the dose reduction taken once daily should be considered (see section 4.4).
Če je to klinično primerno, je treba razmisliti o ponovnem povečanju odmerka na odmerek, kakršen je bil pred zmanjšanjem, ki ga je treba jemati enkrat na dan (glejte poglavje 4.4).
The liver was also identified as a target organ in rats.
Pri podganah se je pokazalo, da so ciljni organ tudi jetra.
Treatment with bosutinib is associated with elevations in serum transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]).
Zdravljenje z bosutinibom je povezano s povečanjem vrednosti serumskih transaminaz (alaninaminotransferaza [ALT], aspartat-aminotransferaza [AST]).
The median duration of therapy was 13.8 months (range: 0.03 to 123.3 months).
Mediano trajanje zdravljenja je bilo 13,8 meseca (razpon: 0,03 do 123,3 meseca).
In addition, 5.6% of patients in the bosutinib treatment group had further dose escalations to 600 mg.
Poleg tega so pri 5,6 % bolnikov iz skupine, ki se je zdravila z bosutinibom, odmerek nadalje povečali na 600 mg.
Overall haematological response (OHR)=major haematological response (complete haematological response + no evidence of leukaemia) or return to chronic phase (RCP).
Celokupni hematološki odziv (OHR) = pomembni hematološki odziv (popolni hematološki odziv + ni nobenega dokaza za levkemijo) ali vrnitev v kronično fazo.
In addition, the patient should be advised that vomiting or diarrhoea may reduce the efficacy of oral contraceptives by preventing full absorption.
Bolnice je treba obvestiti, da lahko bruhanje in diareja zmanjšata učinkovitost peroralnih kontraceptivov, saj preprečujeta popolno absorbcijo.
Bosutinib has demonstrated the ability to absorb light in the UV-B and UV-A range and is distributed into the skin and uveal tract of pigmented rats.
Bosutinib je pokazal sposobnost za absorpcijo svetlobe v območjih UV-B in UV-A; porazdeli se v kožo in uvealni trakt pigmentiranih podgan.
Repeated-dose toxicity studies in rats of up to 6 months in duration and in dogs up to 9 months in duration revealed the gastrointestinal system to be the primary target organ of toxicity of bosutinib.
Študije toksičnosti pri ponavljajočih odmerkih, ki so na podganah trajale do 6 mesecev in na psih do 9 mesecev, so pokazale, da je primarni ciljni organ toksičnosti bosutiniba prebavni sistem.
Therapy should be initiated by a physician experienced in the diagnosis and the treatment of patients with CML.
Zdravljenje mora uvesti zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolnikov s KML.
Population pharmacokinetic analyses in patients with Ph+ leukaemia or malignant solid tumour indicate that there are no clinically relevant effects of age, gender, body weight, race.
Populacijske farmakokinetične analize pri bolnikih s Ph+ levkemijo ali z malignimi čvrstimi tumorji so pokazale, da starost, spol, telesna masa in rasa nimajo klinično pomembnih vplivov.
Experience with bosutinib overdose in clinical studies was limited to isolated cases.
Izkušnje s prevelikim odmerjanjem bosutiniba v kliničnih študijah so omejene le na posamezne primere.
If blood counts remain low for > 2 weeks, upon recovery reduce dose by 100 mg and resume treatment.
Če število krvnih celic ostane majhno > 2 tedna, je po izboljšanju treba odmerek zmanjšati za 100 mg in nadaljevati z zdravljenjem.
Complete blood counts should be performed weekly for the first month and then monthly thereafter, or as clinically indicated.
Popolno krvno sliko je treba preveriti enkrat na teden v prvem mesecu zdravljenja, potem pa enkrat na mesec ali kot je klinično indicirano.
- if you notice any of these symptoms: pain in your side, blood in your urine or reduced amount of urine.
- Če opazite katerega od simptomov: bolečine v ledvenem predelu, kri v urinu ali zmanjšana količina urina.
Bosutinib should be permanently discontinued in patients who experience a severe skin reaction during treatment.
Zdravljenje z bosutinibom je treba trajno prekiniti pri bolnikih, pri katerih se med zdravljenjem pojavi huda kožna reakcija.
A total of 1,272 leukaemia patients received at least 1 dose of single-agent bosutinib.
Skupno 1.272 bolnikov z levkemijo je prejelo vsaj 1 odmerek bosutiniba kot samostojno zdravilo.
The secondary efficacy endpoints included MMR by 18 months, duration of MMR, CCyR by 12 months, duration of CCyR, event-free survival (EFS), and overall survival (OS).
Sekundarni opazovani dogodki učinkovitosti so vključevali MMR po 18 mesecih, trajanje MMR, CCyR po 12 mesecih, trajanje CCyR, preživetje brez dogodkov (EFS - Event-Free Survival) in celokupno preživetje (OS - Overall Survival).
What do you need to know before you take take Bosulif
Kaj morate vedeti, preden boste vzeli zdravilo Bosulif
Return to chronic phase (RCP)=disappearance of features defining accelerated or blast phases but still in chronic phase.
Vrnitev v kronično fazo = izginotje značilnosti, ki določajo pospešeno ali blastno fazo, vendar je bolezen še vedno v kronični fazi.
If a dose is missed by more than 12 hours, take your next dose at your regular time on the following day.
Če ste pozabili vzeti odmerek in je minilo več kot 12 ur, vzemite naslednji odmerek ob običajnem času naslednji dan.
If you faint (loss of consciousness) or have an irregular heartbeat while taking Bosulif, tell your doctor immediately, as this may be a sign of a serious heart condition.
Če med jemanjem zdravila Bosulif omedlite (izgubite zavest) ali imate nereden srčni utrip, nemudoma obvestite zdravnika, saj je to lahko znak resne bolezni srca.
Foetal exposure to bosutinib-derived radioactivity during pregnancy was demonstrated in a placental transfer study in gravid Sprague-Dawley rats.
Izpostavljenost ploda radioaktivno označenemu bosutinibu med nosečnostjo je bila dokazana v študiji prenosa prek posteljice na brejih podganah Sprague-Dawley.
Effects of other medicinal products on bosutinib
Vpliv drugih zdravil na bosutinib
Transaminase elevations generally occurred early in the course of treatment (of the patients who experienced transaminase elevations of any grade, > 80% experienced their first event within the first 3 months).
Vrednosti transaminaz so se običajno povečale zgodaj po začetku zdravljenja (pri > 80 % bolnikov, pri katerih je prišlo do povečanih vrednosti transaminaz katerekoli stopnje, je do prvega dogodka prišlo v prvih treh mesecih).
9/L, no blasts or promyelocytes in peripheral blood, less than 5% myelocytes + metamyelocytes in bone marrow, less than 20% basophils in peripheral blood, and no extramedullary involvement.
9/l, odsotnost blastocitov ali promielocitov v periferni krvi, manj kot 5 % mielocitov + metamielocitov v kostnem mozgu, manj kot 20 % bazofilcev v periferni krvi in odsotnost ekstramedularnih dejavnikov.
Dispose unused medicinal product in accordance with local requirements.
Neuporabljeno zdravilo zavrzite v skladu z lokalnimi predpisi.
These adverse reactions are presented by system organ class and frequency.
Neželeni učinki so našteti glede na organski sistem in pogostnost.
Patients with diarrhoea and vomiting should be managed using standard-of-care treatment, including an antidiarrhoeal or antiemetic medicinal product and/or fluid replacement.
Bolnike z diarejo in bruhanjem je treba obravnavati z uporabo standardnega zdravljenja, ki vključuje antidiaroike ali antiemetike in/ali nadomeščanje tekočine.
Cytogenetic Response criteria: Major Cytogenetic Response included Complete [0% Ph+ metaphases from bone marrow or < 1% positive cells from fluorescent in situ hybridisation (FISH)] or partial (1%-35%) cytogenetic responses.
Merila za citogenetski odziv: pomembni citogenetski odziv je vključeval popolne (0 % Ph+ metafaz iz kostnega mozga ali < 1 % pozitivnih celic iz fluorescenčne “in situ” hibridizacije [FISH]) ali delne (1 %-35 %) citogenetske odzive.
- if you suffer from bleeding problems.
- Če imate težave s krvavitvami.
However, if a patient taking bosutinib experiences dizziness, fatigue, visual impairment or other undesirable effects with a potential impact on the ability to drive or use machines safely, the patient should refrain from these activities for as long as the undesirable effects persist.
Vendar če se pri bolniku med jemanjem bosutiniba pojavijo omotica, utrujenost, motnje vida ali drugi neželeni učinki, ki bi lahko vplivali na sposobnost vožnje ali upravljanja strojev, bolnik ne sme opravljati teh dejavnosti, vse dokler so prisotni neželeni učinki.
Patients will be carefully checked by their doctor for signs of this infection before treatment is started.
Pred začetkom zdravljenja bo zdravnik bolnike skrbno pregledal glede znakov te okužbe.
- Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.
- Ne uporabljajte tega zdravila, če opazite, da je ovojnina poškodovana ali da je že bila odprta.
- Do not use this medicine after the expiry date which is stated on the blister foil and carton after “EXP”.
- Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli poleg oznake “EXP / Uporabno do”.
After a minimum of 12 months of follow-up in the mITT population, 77.6% of patients treated with bosutinib (N=241) and 72.4% of patients treated with imatinib (N=239) were still receiving first-line treatment.
Po najmanj 12 mesecih spremljanja v populaciji mITT je 77,6 % bolnikov, ki so se zdravili z bosutinibom (n = 241), in 72,4 % bolnikov, ki so se zdravili z imatinibom (n = 239), še vedno prejemalo zdravljenje v prvi liniji.
FISH analysis (≥ 200 cells) could be used for post-baseline cytogenetic assessments if ≥ 20 metaphases were not available.
Analizo FISH (≥ 200 celic) je bilo mogoče uporabiti za poznejše citogenetske ocene v primeru, da ne bi bilo na voljo ≥ 20 metafaz.
If bosutinib is used during pregnancy, or the patient becomes pregnant while taking bosutinib, she should be apprised of the potential hazard to the foetus.
Če se bosutinib uporablja v času nosečnosti ali če bolnica zanosi med jemanjem bosutiniba, jo je treba seznaniti z možno nevarnostjo za plod.
Table 3 - Summary of MMR at Months 12 and 18 and CCyR by Month 12, by treatment group in the mITT population
Preglednica 3 - Povzetek MMR po 12 in 18 mesecih ter CCyR po 12 mesecih po skupini zdravljenja v populaciji mITT
Side effects with Bosulif may include:
Neželeni učinki pri jemanju zdravila Bosulif lahko vključujejo:
In vitro testing indicated that bosutinib had limited activity against the T315I or the V299L mutation.
Testiranje in vitro je pokazalo, da ima bosutinib omejeno aktivnost proti mutacijama T315I in V299L.
Four patients (0.3%) experienced QTcF interval prolongation (greater than 500 ms).
Pri 4 bolnikih (0,3 %) se je pojavilo podaljšanje QTcF (večje od 500 ms).
Bosutinib is not recommended for use during pregnancy, or in women of childbearing potential not using contraception.
Bosutiniba ni priporočljivo uporabljati med nosečnostjo ali pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.
Also tell your doctor if you are losing weight or have experienced swelling of your feet, ankles, legs, hands or face.
Prav tako obvestite zdravnika, če izgubljate telesno maso ali če vam otekajo stopala, gležnji, noge, dlani ali obraz.
Table 5 - Efficacy results in previously treated patients with chronic and advanced phase CML*
Preglednica 5 - Rezultati učinkovitosti pri predhodno zdravljenih bolnikih s KML v kronični in napredovali fazi*
Patients with serum creatinine > 1.5 × ULN were excluded from the CML studies.
Bolniki s serumskim kreatininom > 1,5-kratnik ZMN so bili iz študij KML izključeni.
White opaque 3-ply PVC/Polychlorotrifluoroethene/PVC blister sealed with push-through foil backing containing either 14 or 15 tablets.
Bel, neprozoren, troslojen pretisni omot iz PVC/poliklorotrifluoroetena/PVC, zapečaten s folijo na potisk, ki vsebuje 14 ali 15 tablet.
Treatment with bosutinib is associated with diarrhoea and vomiting; therefore, patients with recent or ongoing clinically significant gastrointestinal disorder should use this medicinal product with caution and only after a careful benefit-risk assessment as respective patients were excluded from the clinical studies.
Zdravljenje z bosutinibom je povezano z diarejo in bruhanjem, zato je pri bolnikih z nedavno ali obstoječo klinično pomembno boleznijo prebavil to zdravilo treba uporabljati previdno in šele po skrbni oceni koristi in tveganj, saj so bili ti bolniki iz kliničnih študij izključeni.
Dose reductions are recommended for severe or persistent neutropenia and thrombocytopenia as described in Table 1:
Zmanjšanje odmerkov je priporočljivo pri hudi ali dolgotrajni nevtropeniji in trombocitopeniji, kot je opisano v preglednici 1: